Beyond Air Reports Record Revenue Growth on LungFit PH Adoption…

Event summary

Beyond Air reported preliminary revenue of $2.3 million for Q3 2026, up 30% sequentially and 27% year-over-year.
Revenue growth driven by continued adoption of the first-generation LungFit PH system.
Company reaffirmed full-year 2026 revenue guidance of $8 million and 2027 guidance of $16-$18 million.
Second-generation LungFit PH system remains under FDA review.
Full Q3 2026 financial results to be reported in November 2026.

The big picture

Beyond Air's record revenue growth underscores the increasing adoption of its nitric oxide delivery system in hospitals. The company's ability to scale its infrastructure and secure FDA approval for its second-generation system will be critical in maintaining its market position. The medical device and biopharmaceutical sectors continue to focus on innovative solutions for respiratory illnesses, with nitric oxide technology emerging as a key area of growth.

What we're watching

Regulatory Approval: The pace at which the FDA reviews the second-generation LungFit PH system will determine Beyond Air's ability to meet its ambitious 2027 revenue guidance.
Market Adoption: Whether Beyond Air can sustain its 30% sequential growth rate as it scales its commercial execution strategy.
Competitive Positioning: How the company's cylinder-free nitric oxide technology will perform against traditional high-pressure NO cylinder systems in the hospital setting.